别名 NPC1L1蛋白受体、Niemann-Pick C1-like protein 1、NPC1 (Niemann-Pick disease, type C1, gene)-like 1 + [6] |
简介 Plays a major role in cholesterol homeostasis (PubMed:22095670). Critical for the uptake of cholesterol across the plasma membrane of the intestinal enterocyte (PubMed:22095670). Involved in plant sterol absorption, it transports sitosterol, although at lower rates than cholesterol (By similarity). Is the direct molecular target of ezetimibe, a drug that inhibits cholesterol absorption and is approved for the treatment of hypercholesterolemia (PubMed:15928087). May have a function in the transport of multiple lipids and their homeostasis, thereby influencing lipid metabolism regulation (PubMed:15671032). May be involved in caveolin trafficking from the plasma membrane (By similarity). In addition, acts as a negative regulator of NPC2 and down-regulates its expression and secretion by inhibiting its maturation and accelerating its degradation (PubMed:22095670). |
靶点 |
作用机制 NPC1L1抑制剂 [+1] |
在研机构 |
原研机构 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2021-06-25 |
作用机制 ACL抑制剂 [+2] |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2020-02-26 |
作用机制 HMG-CoA reductase抑制剂 [+2] |
在研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期2019-03-26 |
开始日期2024-10-04 |
申办/合作机构 |
开始日期2024-10-01 |
申办/合作机构 |
开始日期2024-08-14 |
申办/合作机构 |